PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
+20.97%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$815M
AUM Growth
+$815M
(+15%)
Cap. Flow
+$60M
Cap. Flow
% of AUM
7.37%
Top 10 Holdings %
Top 10 Hldgs %
31.52%
Holding
117
New
28
Increased
37
Reduced
32
Closed
17
Top Buys
| 1 |
Eli Lilly
LLY
|
$25M |
| 2 |
Cooper Companies
COO
|
$21.3M |
| 3 |
Fortrea Holdings
FTRE
|
$17.2M |
| 4 |
Schrodinger
SDGR
|
$16.1M |
| 5 |
Oscar Health
OSCR
|
$12.4M |
Top Sells
| 1 |
Amgen
AMGN
|
$17.7M |
| 2 |
Boston Scientific
BSX
|
$15.6M |
| 3 |
Keros Therapeutics
KROS
|
$12.1M |
| 4 |
Mettler-Toledo International
MTD
|
$9.1M |
| 5 |
Humana
HUM
|
$8.28M |
Sector Composition
| 1 | Healthcare | 99.46% |
| 2 | Industrials | 0.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Tenet Healthcare
THC
$16.3B
| $29.8M | 3.66% | 283,853 -72,953 | -20% | -$7.67M |
|
2
United Therapeutics
UTHR
$13.8B
| $29.4M | 3.61% | 128,199 -33,340 | -21% | -$7.66M |
|
|
3
Boston Scientific
BSX
$156B
| $29.1M | 3.58% | 425,473 -227,330 | -35% | -$15.6M |
|
|
4
Cooper Companies
COO
$13.4B
| $29M | 3.55% | 285,399 +210,216 | +280% | +$21.3M |
|
|
5
Schrodinger
SDGR
$1.44B
| $27M | 3.31% | 1,000,014 +594,782 | +147% | +$16.1M |
|
|
6
Eli Lilly
LLY
$657B
| $25M | 3.07% | +32,117 | New | +$25M |
|
7
DexCom
DXCM
$29.5B
| $23.8M | 2.92% | 171,665 -53,950 | -24% | -$7.48M |
|
8
Cencora
COR
$56.5B
| $23.8M | 2.92% | 97,905 -4,986 | -5% | -$1.21M |
|
9
RxSight
RXST
$370M
| $21.3M | 2.61% | 412,432 -100,600 | -20% | -$5.19M |
|
10
Syndax Pharmaceuticals
SNDX
$1.41B
| $18.7M | 2.29% | 784,811 +46,222 | +6% | +$1.1M |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $18.2M | 2.23% | 131,951 -8,165 | -6% | -$1.13M |
|
12
Inspire Medical Systems
INSP
$2.77B
| $17.4M | 2.14% | 81,183 -22,563 | -22% | -$4.85M |
|
|
13
Fortrea Holdings
FTRE
$894M
| $17.2M | 2.11% | +427,804 | New | +$17.2M |
|
14
Insulet
PODD
$23.9B
| $15.6M | 1.91% | 90,949 +2,274 | +3% | +$390K |
|
|
SILK
15
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $15.6M | 1.91% | 848,897 +303,662 | +56% | +$5.56M |
|
|
LBPH
16
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $15M | 1.84% | 693,144 +263,252 | +61% | +$5.69M |
|
17
Abbott
ABT
$231B
| $13.8M | 1.7% | 121,689 -35,038 | -22% | -$3.98M |
|
18
Qiagen
QGEN
$10.1B
| $13.5M | 1.66% | 313,954 +63,954 | +26% | +$2.75M |
|
|
BCYC
19
Bicycle Therapeutics
BCYC
$511M
| $13.1M | 1.6% | 524,253 +211,364 | +68% | +$5.26M |
|
20
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $12.7M | 1.56% | 646,163 +30,470 | +5% | +$601K |
|
21
Applied Therapeutics
APLT
$71M
| $12.6M | 1.55% | 1,854,763 +835,607 | +82% | +$5.68M |
|
|
22
Oscar Health
OSCR
$4.31B
| $12.4M | 1.52% | +831,283 | New | +$12.4M |
|
23
Edgewise Therapeutics
EWTX
$1.51B
| $11.9M | 1.46% | 653,653 +2,028 | +0.3% | +$37K |
|
|
24
Keros Therapeutics
KROS
$618M
| $11.8M | 1.45% | 178,335 -182,132 | -51% | -$12.1M |
|
25
HCA Healthcare
HCA
$94.5B
| $11.8M | 1.44% | +35,283 | New | +$11.8M |
|